Recovery · Peptide Reference · Updated 2026-05-11

TB-500

Synthetic peptide based on thymosin beta-4. Promotes cell migration, actin filament regulation, and tissue repair. Used for soft-tissue, tendon, and ligament injuries.

Recovery Evidence grade: C Not FDA-approved
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Key facts

Class
Synthetic peptide (Thymosin Beta-4 fragment)
Half-life
~2 hours after SC injection
Pharmacy pathway
503A compounding
Sports-ban status
WADA prohibited (S0 — Non-Approved Substances)
Common stack
BPC-157 ("Wolverine stack")
Common dose
2.0-2.5 mg SC twice weekly for 4-6 weeks loading; 2 mg weekly maintenance
Evidence grade
C (animal data; veterinary use in racehorses)
FDA status
Not FDA-approved (compounded)

Mechanism of action

Synthetic peptide based on thymosin beta-4. Promotes cell migration, actin filament regulation, and tissue repair. Used for soft-tissue, tendon, and ligament injuries.

Standard dosing

Typical clinical use: 2.0-2.5 mg SC twice weekly for 4-6 weeks loading; 2 mg weekly maintenance. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. TB-500 requires a prescription from a licensed clinician.

Regulatory status & pharmacy pathway

Not FDA-approved (compounded). Compounded peptides are dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). Patients should request the pharmacy of record and certificates of analysis (USP <71> sterility, USP <85> endotoxin, HPLC potency) for every shipment.

U.S. telehealth providers prescribing TB-500

The most commonly cited U.S. telehealth providers for TB-500 are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD — all of which offer prescriber-supervised access with lab integration and 503A pharmacy partnerships. See the full provider directory for complete profiles.

Trade-offs to know

TB-500 carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved (when applicable), cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that publishes pharmacy of record, per-vial CoAs, and lab-integrated follow-up.

Related peptides in the recovery category

Editorial team

Authored by Dr. Sam Saberian, medically reviewed by Alen A. Schwartz, MD, edited by Julliana Edwards. About our team →